Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Nov 14, 2013 · 10-Q · 45 days after period end · 0001415889-13-002318
| Metric | Q2 2014 | Q2 2010 |
|---|---|---|
| Revenue | — | $399.58K |
| Net Income | -$1.46M | -$1.57M |
| EPS Diluted | -$1.37 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Sep 30, 2013 · filed Nov 14, 2013 · 45 d after period end
